Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2019-06-05
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of lenalidomide when given
together with cytarabine in treating patients with relapsed or refractory acute myeloid
leukemia (AML). Biological therapies, such as lenalidomide, may stimulate the immune system
in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as
cytarabine, work in different ways to stop the growth of cancer cells, either by killing the
cells or by stopping them from dividing. Giving lenalidomide together with cytarabine may
kill more cancer cells
Phase:
Phase 1
Details
Lead Sponsor:
Roswell Park Cancer Institute
Collaborators:
Celgene Corporation National Cancer Institute (NCI)